α-synuclein/CHMP2B

α-synuclein/CHMP2B connects synuclein biology with ESCRT-III-dependent endolysosomal trafficking, because CHMP2B functions within the ESCRT-III complex and α-synuclein is transported through multivesicular bodies for degradation^[1]. Mechanistically, α-synuclein targets CHMP2B degradation, disrupts ESCRT transport, increases α-synuclein exocytosis, and may promote cell-to-cell propagation in Lewy body disease models^[1]. In α-synuclein transgenic mice, lentiviral CHMP2B overexpression reduced α-synuclein accumulation and rescued neurodegeneration, supporting CHMP2B as a practical experimental modifier of synucleinopathy pathways^[1]. Genetic evidence also links CHMP2B to neurodegeneration, because CHMP2B mutations in a chromosome 3-linked frontotemporal dementia pedigree caused aberrant mRNA splicing^[2]. Compared with related ESCRT-III components, CHMP2B is the directly defined α-synuclein interaction node, as a peptide inhibitor disrupted binding between the α-synuclein C-terminal region and CHMP2B^[3]. For research applications, this peptide inhibitor restored endolysosomal function, lowered α-synuclein levels, and protected dopaminergic neurons in human cell, C. elegans, and rat Parkinson’s disease models^[3]. Recent Molecular Cell data further show that α-synuclein fibrils sequester ESCRT-III subunits and trigger collateral proteasomal degradation, reinforcing ESCRT-III depletion as a mechanistic focus for α-synuclein/CHMP2B studies^[4].